News, Media & Events
March 2nd, 2010
U.S. Food and Drug Administration (FDA) Sets 22 March for Oncologic Drugs Advisory Committee (ODAC) Meeting to Review OMAPRO™
MELBOURNE, Australia, and MENLO PARK, California USA (2 March 2010) – ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010.
The ODAC meeting will consider ChemGenex’s application for OMAPRO™ (omacetaxine mepesuccinate) for the treatment of adults [...]
February 9th, 2010
Extreme Weather in Washington D.C. has Postponed the FDA’s Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010
MELBOURNE, Australia, and MENLO PARK, California USA (9 February 2010) – ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the Oncologic Drugs Advisory Committee (ODAC) public advisory meeting scheduled for 10 February 2010 has been suspended due to extreme weather conditions in Washington D.C..
The [...]